The biggest buzz around GLP-1 drugs these days has nothing to do with weight loss. And that might lead to some problems for patients and insurers. Blockbuster treatments like Ozempic have been found to lower the risk of everything from Alzheimer's and addiction, to sleep apnea, seizures and bacterial infections. More potential uses keep surfacing.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
